Hutchmed (China) Ltd on Thursday said its supplemental new drug application for savolitinib has been accepted for review by the China National Medical Products Administration.
If accepted, the Hong Kong-based developer of treatments for cancer and immunological diseases said that the new label indication for savolitinib will be expanded to include treatment-naive patients in China.
A treatment-naive patient is someone who has not received any treatment.
Savolitinib is a treatment for adult patients with locally advanced or metastatic non-small cell lung cancer. It had previously been granted conditional approval in China. ‘
More than a third of the world’s lung cancer patients are in China,’ Hutchmed said.
Shares in Hutchmed were flat at $16.69 each in London on Thursday morning.
Copyright 2024 Alliance News Ltd. All Rights Reserved.
